Point of Care Ultrasound For The Diagnosis Of Deep Venous Thrombosis And Its Effect On Length Of Hospital Stay

Overview

This is a Clinical Trial on the use of Point Of Care Ultrasound for the diagnosis of deep venous thrombosis (DVT) and its effect on length of hospital stay. 25 participants with suspicion of DVT according to Wells Criteria were randomized to one of two groups: Point of Care Ultrasound and Echo Doppler Ultrasound (POCUS + EDUS), and the control group was submitted only to the Echo Doppler Ultrasound (EDUS). The primary outcome was hospital stay.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: Single (Investigator)
  • Study Primary Completion Date: November 30, 2016

Detailed Description

Because of high mortality associated with venous thrombosis (pulmonary embolism and deep venous thrombosis – DVT) the early recognition and therapeutics of its condition are crucial. Point of Care Ultrasound (POCUS) is a method with high sensibility to diagnose DVT and it is as accurate as Echo Doppler Ultrasound (EDUS), however the use of POCUS for diagnosis of DVT in the emergency care still presents resistance. This is a Clinical Trial on the use of POCUS for the diagnosis of DVT and its effect on length of hospital stay. 25 participants were randomized into two groups. The randomization was done through the random.org site in blocks of 4, a randomization list was with one researcher (blind) of the study. The experimental group was first submitted to POCUS in the Emergency Room, performed by a resident physician of Internal Medicine with training in POCUS, then after submitted to EDUS in the Radiology Service by a Radiologist. The control group was submitted only to EDUS in the Radiology Service. The 2-point compression technique was used, as described in previous studies, using the portable ultrasound device (M-turbo Sonosite) with a high frequency linear transducer (5-10 MHZ). The sites used in the evaluation were the popliteal site comprising the popliteal vein and trifurcation of the popliteal vein and the femoral point in which comprises the sapheno-femoral junction, the common femoral vein and the superficial femoral vein, all evaluated in the transverse plane. The result was considered positive for DVT when the vessel evaluated showed no compressibility and / or presented echogenic material in the lumen of the vein. After the randomization, the patients were followed for a period of 30 days, being evaluated in three moments: initial evaluation, at 7 and 30 days of the initial evaluation. Whenever possible, each evaluation was in person. In the initial evaluation, the participant's demographics, date and time of arrival at the Emergency Service, previous illnesses, Wells criteria score and reason for the initial care were collected. Participants randomized to the POCUS + EDUS group had recorded date and time of ultrasound at the bedside and, if there was confirmation of DVT, these data were collected by the resident physician, blinded for the Echo Doppler Ultrasound results. EDUS data, such as date and time of the examination request, date and time of the release of the exam report, confirmation of DVT, date and time of discharge were collected by another researcher, blinded to the participant's group and to the POCUS's results. After 7 and 30 days the outcomes were recorded: time for a first diagnostic information, time to therapeutic decision making / prescription, length of hospital stay, death, pulmonary thromboembolism, bleeding or other complication, re-hospitalization, evolution to DVT in cases that were initially negative.

Interventions

  • Diagnostic Test: Point Of Care Ultrasound (PODUS)
    • Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
  • Diagnostic Test: Echo Doppler Ultrasound (EDUS)
    • Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.

Arms, Groups and Cohorts

  • Experimental: POCUS + EDUS
    • Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
  • Active Comparator: Echo Doppler Ultrasound (EDUS)
    • Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.

Clinical Trial Outcome Measures

Primary Measures

  • Length of hospital stay
    • Time Frame: Up to 30 days
    • Length of hospital stay

Secondary Measures

  • Time to first diagnostic information
    • Time Frame: Up to 30 days
    • Time to first diagnostic information
  • Time to therapeutic decision making / prescription
    • Time Frame: Up to 30 days
    • Time to therapeutic decision making / prescription

Participating in This Clinical Trial

Inclusion Criteria

  • Low, moderate or high suspicion of DVT by Wells Criteria. – Patients with Echo-Doppler Ultrasonography already requested in the hospital system. Exclusion Criteria:

  • Myocardial Infarction, Stroke or Cardiac Surgery within 3 months prior to hospital admission; – Renal Chronic Disease (Clinical Stages IV and V); – Congestive Heart Failure (NYHA IV); – Pregnancy; – Previous episode of DVT in the same leg that of the current DVT suspicion; – Patients already in treatment for DVT or taking anticoagulants for any other reason.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Hospital de Clinicas de Porto Alegre
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ana Claudia Tonelli, Principal Investigator, Hospital de Clinicas de Porto Alegre

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.